Clinical review report : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults. Brexpiprazole (Rexulti) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Outcome assessment (Medical care)--Methodology.

Physical Description:

1 online resource

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist activity at serotonergic 5-HT2A receptors. The recommended dosage is 2 mg to 4 mg once daily. The product monograph recommends a starting dosage of 1 mg per day on days 1 to 4, titrated to 2 mg once daily on days 5 to 7, and then to 4 mg on day 8, based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg for most patients. The manufacturer has requested that brexpiprazole be reimbursed in accordance with the Health Canada-approved indication (i.e., for the treatment of schizophrenia in adults).

Notes:

Description based on publisher supplied metadata and other sources.